May 2018
NCI Standard Funding Opportunity Announcements | |||||||||||||||||||||
| Current and Recent Program Announcements | Current and Recent Requests for Applications | |||||||||||||||||||||
|
Current
and Recent NCI and Trans-NIH Initiatives |
Requests for Proposals
|
Standard Due Dates |
|||||||||||||||||||||
 |
Adenoid Cystic Carcinoma Research Foundation
Projects supported by ACCRF fall into three broad categories:
| ||||||||||||||||||||
| Due Dates: | Continuous - Researchers wishing to submit a proposal should email ACCRF's Executive Director w/a 1 paragraph description of research project. If determined to be w/in research priorities, a request for a full proposal will be issued. |
| Amount & Project Period: | Not stated |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| Links: |
Grant Opportunities ACCRF Research Agenda |
Leading the Crusade to find a cure for Leukemia
NEW
| Continuous | All Ranks | Non-federal | Blood Cancers |
The Ryan Gibson Foundation
Research that Saves - Grants
Research grant requests from around the country are welcomed at
any time. The main focus is on blood related cancers.| Due Dates: | A one to two page proposal can be submitted any time. |
| Amount & Project Period: | Not stated. Budget and performance period requested should be reasonable in accordance with project proposed. |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | Research that Saves - Grants |
Pre-announcements
| To Be Announced | See Announcements | Federal | See Specific Program |
Congressionally Directed Medical Research Programs
Upcoming Funding Opportunities
Although funds have not been appropriated for FY18, CDMRP is providing
information in these pre-announcements to allow investigators
time to plan and develop ideas for submission to the anticipated
FY18 funding opportunities. Pre-Announcements have been issued
as follows. Click on the link for additional information.1. Department of Defense Peer Reviewed Medical Research Program Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)
2. Department of Defense Ovarian Cancer Research Program Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)
3. Department of Defense Bone Marrow Failure Research Program Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)
4. Department of Defense Breast Cancer Research Program Anticipated Funding Opportunities for Fiscal Year 2018
5. Department of Defense Lung Cancer Research Program Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)
6. Department of Defense Peer Reviewed Cancer Research Program Funding Opportunities for Fiscal Year 2018 (FY18)
7. Department of Defense Prostate Cancer Research Program Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)
NEW
| April 16 & 17 (LOIs) | Faculty - See Below | Non-federal | Breast |
Metavivor
2018 Funding Opportunities
METAvivor funds research focused on treating established breast
cancer metastases to improve outcomes for stage IV metastatic
breast cancer patients. Research on prevention or diagnosis of
breast cancer metastasis is not funded.
| Contact: | Office of Sponsored Research (x6804) |
| Primary Link: | METAvivor Funding Opportunities |
Metavivor Research Award (MRA)
The goal of this funding call is to support established investigators in creating a foundation for basic, translational, and clinical research designed to address critical problems or barriers to progress in the field of metastatic breast cancer.| Due Dates: | Apr. 17 (Letter of Intent) Invited Applications Due: Aug. 02 (OSR) Ι Aug. 6 (Sponsor) |
| Amount & Project Period: | $200,000 - 2 years (2nd yr. dependent on
approval of year 01 progress report |
| Eligibility: | Established Investigators U.S. citizenship not required; proof of permanent resident status or a valid work visa is required if applicant is not a U.S. citizen. |
| Links: | Guidelines |
METAvivor Early Career Investigator Award (ECIA)
The ECIA is meant to support novel, high-quality research in metastatic breast cancer performed by the most promising up-and-coming investigators. The goal is to provide a supporting foundation for basic, translational, and clinical research designed to address critical problems or barriers to progress in the field of metastatic breast cancer.| Due Dates: | Apr.
16 (Letter of Intent) Invited Applications Due: Aug. 02 (OSR) Ι Aug. 6 (Sponsor) |
| Amount & Project Period: | $50,000 - 1 year |
| Eligibility: | Must be w/in 6 years of starting first
non-tenured position or w/in 10 years of receiving professional degree; May hold title of Postdoc, Instructor, Research Assoc, Asst. Professor or equiv. At start of grant, applicant cannot hold title of Assoc. Professor or hold a tenured position; U.S. citizenship not required; proof of permanent resident status or a valid work visa is required if applicant is not a U.S. citizen. |
| Links: | Guidelines |
| April 23, 3:00pm ET | All Faculty Ranks | Non-federal | Prostate Cancer |
Prostate Cancer Foundation
2018 PCF Challenge Awards for Metastatic, Lethal Prostate
Cancer
The Request for Team Science Applications for PCF Challenge Awards is open. Funding will be based on the level of innovation in applications
received. Research proposals in the following topic areas are
preferred:1. Immunotherapy for treatment of metastatic, lethal prostate cancer;
2. Targeted radionuclide therapy for advanced prostate cancer;
3. New systemic precision treatments for metastatic, lethal prostate cancer including those
targeting the currently "undruggable";
4. First-in-field research on new targets for systemic treatment of metastatic, lethal prostate
cancer;
5. Mechanisms of resistance to current and investigational drugs targeting the androgen
receptor and androgen axis, immune system, chemotherapy, and other targeted agents;
6. Correlative research around either clinical trials of novel agents or strategies or standard
of care;
7. Developing or validating biomarkers that guide therapy in patients or further
understanding of mechanisms by which therapies work;
8. Tumor microenvironment signaling related to cancer progression including the immune
component;
9. New bioinformatics technologies for analysis of genomic data and big data of clinical
outcomes.
| Due Dates: | Apr. 19 (OSR) Ι Apr. 23 (Sponsor, 3:00pm ET) |
| Amount & Project Period: | Up to $1M (Total) - 2 years |
| Eligibility: | Team should be
composed of at least 3 investigators capable of providing unique
scientific expertise; May be assembled from one institution, or several institutions; Must embed at least one young investigator as an integral contributor; Young investigator may hold title of Postdoc, Instructor, Research Assoc., Asst. Professor, or equiv., and be w/in 6 years of completing a professional degree (MD, DO, PhD, MD-PhD, DSc, ScD, DDM, DDS, DMD, MBBS, or equiv.) or subsequent mentored academic or clinical training program; S/he must have been awarded no more than $200,000 in direct research funding from all sources including institutional funds during the 2-year term of this award. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | RFA Ι SmartSimple (Submission site) Ι PCF for Researchers |
| April 23 | All Ranks | Non-federal | Patient Care |
Florida Blue Foundation
Improve Consumer Health
The purpose is to fund programs that support one or both of the
following funding areas:
1. Innovative programs that
propose evidence-based health solutions that serve underserved,
underinsured and low-income populations;2. Access to affordable, non-traditional health services (e.g., telehealth, "meet them where they live" and other solutions).
| Due Dates: | Apr. 19 (OSR) Ι Apr. 23 (Sponsor) |
| Amount & Project Period: | Average yearly is $80,000 - $100,000 - 3 or 4
years Priority given to applicants including collaborations and partnerships with other nonprofit organizations in Florida |
| Eligibility: | Must be
based in Florida; Must have capacity, expertise, resources, knowledge in the field and time needed to carry out intent of project; Must have expertise in delivering educational and awareness programs on targeted topics to targeted populations described in this application; Must have a five-year or longer track record in one or both of the funding areas; Must have capability to reach target populations described in application |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | Improve Consumer Health |
NEW
| April 27 (LOI) | All Ranks | Non-federal | Clinical Studies/Breast |
Pfizer
ASPIRE Breast Cancer Research Awards
Pfizer is interested in supporting clinical studies in breast
cancer, focusing in the following areas: Hormone receptor positive (HR+) advanced breast cancer, safety and efficacy profile of palbociclib/hormone therapy given concurrently with radiation in patients with bone disease; HER2-advanced breast cancer, safety and efficacy profile of talazoparib novel combination (except CDK4/6 inhibitors) in patients with HRD/DDR deficiency;
HER2-advanced breast cancer, safety and efficacy profile of gedatolisib plus talazoparib combination in appropriate patients; and early stage breast cancer setting, translational end point driven study to explore potential effect of gedatolisib on immune system in regard to PD-1, PD-L1, TILs, and other appropriate markers, with or without an immunotherapy agent.
| Due Dates: | Apr. 27 (Letter of intent-submit by email to
ASPIREonc@pfizer.com) Invitation to submit full protocols issued: May, 2018 |
| Amount & Project Period: | $$ not stated - Duration: 24 - 30 months |
| Eligibility: | PI must have a
medical degree (MD or equivalent), or an advanced nursing degree (RN
with a MS/PhD); PI and sponsoring organization must be located in U.S. and Study must take place entirely in U.S. (all sites must be located in U.S.). |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | 2018 ASPIRE Breast Cancer Research Awards Program |
| R01 | NCI |
| April 30 (LOI) | All Ranks | Federal | Cancer Imaging |
Perception and Cognition Research to Inform Cancer Image Interpretation (Clinical Trial Optional)
The purpose of this FOA is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.| Due Dates: | Apr. 30 (Letter of Intent, Optional) Applications Due: May 25 (OSR) Ι May 30 (Sponsor) Additional Due Dates: Sept. 26th and May 30, & Sept. 26, 2019 |
| Amount & Project Period: | Application budgets not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-640 |
| Companion FOA: | PAR-18-641, R21 |
| April 30 | All Ranks | Non-federal | Research Projects |
Elsa U. Pardee Foundation
Research Grants
The Foundation
funds research directed toward identifying new treatments or
cures for cancer, and particularly encourages applications
allowing establishment of capabilities of new cancer
researchers, or new cancer approaches by established cancer
researchers.| Due Dates: | Apr. 26 (OSR) Ι Apr. 30 (Sponsor) Additional Annual Due Dates: Aug. 31 and Jan. 31 |
| Amount & Project Period: | Funding amounts not specified - generally one year |
| Eligibility: | All Ranks - new cancer researchers or new approaches by established cancer researchers |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | Grant Application Process |
NEW
| April 30 (LOI) | All Ranks | Non-federal | Vulnerable Populations |
Rita & Alex Hillman Foundation
Hillman Emergent Innovation Program
The purpose is to accelerate the development of bold, nursing-driven
interventions targeting the needs of vulnerable populations.
Sought are creative, early stage (pre-evidence or untested)
innovations that target health and health care problems in new
ways. Priority consideration will be given that include one or
more of the following: (1) Engagement of patients, families,
caregivers, and/or community organizations; (2)
Inter-professional or multidisciplinary collaboration; (3)
Institutional and community partnerships; (4) Provision of care
in non-hospital settings; (5) Measurable goals and outcomes.
| Due Dates: | Apr. 30 (Letter of Intent) Invited Submissions: Jul. 19 (OSR) Ι Jul. 23 (Sponsor) |
| Amount & Project Period: | $50,000 - 1 year |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | Program Overview | RFP |
| U01 (Also see Companion RFAs) | NCI |
| April 30 (LOI) | All Ranks | Federal | NCI-supported Technology |
Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (Clinical Trial Optional)
The purpose is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects proposing to expand upon original research question(s) or otherwise accelerate progress for parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.| Due Dates: | Apr. 30 (Letter of Intent, Optional) Applications Due: May 25 (OSR) Ι May 29 (Sponsor) Additional 2018 Due Dates: Sept. 28 |
| Amount & Project Period: | Not to exceed $150,000/yr. (Direct Costs) - up to 2 years, but not to exceed remaining number of years on parent grant. If a no-cost extension is needed on parent grant, it must be in place before revision application is submitted. |
| Eligibility: | All Ranks - Revision applications from active NCI U01 awardees. |
| Contact: | Office of Sponsored Research (x6804) |
| RFA Link: | RFA-CA-18-007 |
| Companion RFAs: |
RFA-CA-18-006, R01 Research Project Grant RFA-CA-18-008, P50 Research Project - Cooperative Agreements RFA-CA-18-009, P01 Program Project Grant RFA-CA-18-010, U54 Resource-Related Research Projects - Cooperative Agreements |
| May 01 (LOI) | Junior Faculty | Federal | Career Development |
Air Force Office of Scientific Research
2019 Young Investigator Program (YIP)
FA9550-18-S-0002
This program intends support for young career scientists and
engineers who have received Ph.D. or equivalent degrees by 1
April 2012 or later and who show exceptional ability and promise
for conducting basic research. See "Research
Interests of the Air Force Office of Scientific Research" | Due Dates: | May 01 (Letter of Intent) Jul. 30 (OSR) Ι Aug. 01 (Sponsor) |
| Amount & Project Period: | $450,000 - 3 years |
| Eligibility: | Must be U.S.
citizen, national, or permanent resident; See Section C.3.a.
Primary Investigator Employment Requirements in announcement; Must have rec'd. doctorate no earlier than April 01, 2012; Must hold full-time permanent, career- competitive, or tenure-track position. |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | FA9550-18-S-0002 |
| May 01 | All Ranks | Non-federal | Breast/Education |
Florida Breast Cancer Foundation (FBCF)
Education Grants
FBCF seeks to fund resourceful and innovative educational
projects in four key areas:1. Breast cancer education;
2. Survivorship education;
3. Provide education on breast health to young women and men;
4. Late stage breast cancer education
Please note that funding is not available for screening, treatment programs, one-time events, conferences, symposiums, seminars, and participation as an exhibitor, presentation, or attendance at health fairs, conferences, symposiums, and seminars.
| Due Dates: | Apr. 27 (OSR) Ι May 01(Sponsor) Electronic & Hardcopy |
| Amount & Project Period: | Up to $5,000 for projects in a single county;
Up to $10,000 for projects provided in multiple counties focusing on education in one on one or small group settings Duration: 1 year |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| Links: |
Breast Cancer Education Download 2018 Education RFP |
| May 01 | All Ranks | Non-federal | Pediatric Cancers |
Pediatric Cancer Research Foundation (PCRF)
2018 Grant Cycle
The Foundation offers funding in three areas: Basic Science Grants, Translational Research Grants and Emerging Investigator Fellowship Grants. | Due Dates: | Apr. 26 (OSR) Ι May 01 (Sponsor) |
| Eligibility: | All Ranks (Please see Emerging Investigator Fellowship Grant for additional eligibility detail) |
| Contact: | Office of Sponsored Research (x6804) |
| Links: |
PCRF Grant Cycle proposalCENTRAL (Grant Procedure &Submission site) |
Basic Research Science Grant
These awards primarily fund basic science, translational and/or clinical state of the art pediatric cancer research initiatives.| Amount & Project Period: | Up to $250,000/yr. - Duration is project dependent |
Translational Research Grant
These awards primarily fund new research protocols and therapies that hold promise for improved outcomes and accelerates cures from the laboratory bench to the bedside of children and teens with high-risk cancers. This Grant will be given to a program that involves open, multi-institutional cancer clinical trials, or consortia, and implements new approaches to therapy.| Amount & Project Period: | Up to $100,000/ yr. - Duration is project dependent |
Emerging Investigator Fellowship Grant
This award is designed to support Post-Doctoral Fellowships and Clinical Investigator training for emerging pediatric cancer researchers to pursue exciting research ideas.| Amount & Project Period: | Up to $50,000/yr. Can be renewed annually |
| Eligibility: | Applicants must
have completed two years of a fellowship, or Not more than two years as a junior faculty instructor or assistant professor at start of award period. |
| May 01 | Faculty Ranks (See Below) | Non-federal | Hematology |
American Society of Hematology (ASH)
Bridge Grants
The purpose of Bridge
grants is to provide support for ASH members who have applied for an NIH R01 or equivalent
award but have been denied funding due to budget cutbacks. These
grants are intended to help sustain recipients' research.| Due Dates: | Apr. 27 (OSR) Ι May 01 (Sponsor) |
| Amount & Project Period: | $150,000 - 1 year |
| Eligibility: | Must have
submitted a hematology-related R01 or R01-equiv. application
in past 18 months that was scored but not funded; may include a
first-time submission (18 month timeframe begins on date of NIH study
section review); Must have $50,000 matching commitment from institution identifying use of commitment (Inadequate documentation of match may result in rejection of application prior to review); Must be an ASH member in good standing (membership may be pending at time of application but must be approved by award activation; Must hold a faculty appointment; Other research funding may not exceed $250,000 annually. |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | Apply for the ASH Bridge Grant |
| May 01 (LOI) | Postdocs/Junior Faculty | Non-federal | Hematology/Career Development |
American Society of Hematology
ASH Scholar Awards
The purpose of the ASH Scholar Awards is to provide partial
support during the period between completion of training and
establishment of independent career. ASH supports
Basic/Translational research and Clinical/Translational
research to include patient-oriented and outcome-based
research.| Due Dates: | May 01 (Letter of Intent) Applications Due: Jul. 30 (OSR) Ι Aug. 01 (Sponsor) |
| Amount & Project Period: | Fellow Scholars : $100,000 - 2 to
3 years Junior Faculty Scholars: $150,000 - 2 to 3 years |
| Eligibility: | Must be ASH
member in good standing at submission of LOI and for
duration of award; Must be U.S. citizen or hold current/valid visa; Research must be conducted in U.S.; Please see Eligibility Requirements for specifics related to Fellow Scholars and Junior Faculty Scholars; |
| Contact: | Office of Sponsored Research (x6804) |
| Links: |
Scholar Award ASH Scholar Award Terms and Conditions |
| K18 | NIH |
| May 01 | Established Investigators | Federal | Career Development |
Short-term Mentored Career Enhancement Awards for Mid-Career Investigators to Integrate Basic Behavioral and Social Sciences (Clinical Trial Required)
This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-18-349).| Due Dates: | Apr. 27 (OSR) Ι May 01 (Sponsor) Additional Due Date: April 13, 201 |
| Amount & Project Period: | Up to $80,000/yr. for salary; $20,000/yr. research development costs; Duration: 1 year |
| Eligibility: |
Award is intended for well-established investigators
w/established records of independent, peer-reviewed Federal or private
research grant funding. Candidate must have a research or health-professional doctoral degree. Candidate must have a "full-time" appointment, and is required to commit at least 50% effort (i.e., a minimum of 6 person-months) to their program of career development. |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-692 |
| Companion FOA: | PAR-18-349 (K18 - No Independent Clinical Trials) - Next due date is March 6, 2019 |
EXTENDED DUE DATE
| May 02 (Extended from 03/02) | All faculty Ranks | Non-federal | Lung Cancer |
AACR-J&J Lung Cancer Innovation Science Grants
This grant represents a joint effort to address this need by promoting and supporting pioneering cancer research. Proposals should focus on understanding the behaviors that lead to chronic exposures to respiratory carcinogens and how these behaviors can be modified; how chronic exposures produce cellular/genomic damage and how these can be ameliorated; deciphering the types of inflammation that underlie the carcinogenic process; understanding the alterations in innate and adaptive immunity that create an immune-permissive microenvironment; and changes in the pulmonary microbiome that may contribute to carcinogenesis. Proposals that characterize premalignant lesions or that substantially improve the detection of lung cancer at more curable stages will also be prioritized.| Due Dates: | Apr. 30 (OSR) Ι May. 02 (Sponsor) |
| Amount & Project Period: | $1.5M (TOTAL) - 3 years |
| Eligibility: | Independent
investigators at all levels; At least 2, but no more than 3, co-applicants serving as Co-PIs from distinct institutions are required (the lead PI is responsible for application); Only one application per lead PI will be accepted, although individuals may serve as a co-PI or contribute to more than one application. Project Team should also include at least 1 young investigator (e.g., postdoctoral or clinical research fellow; junior faculty member); Non-citizens or permanent residents must assure that visa status will provide sufficient time to complete project and grant term at institution from which application submitted. AACR membership is required. Nonmembers must submit satisfactory application for AACR Active Membership by Friday, March 2, 2018. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: |
AACR-J&J Lung Cancer Innovation Science Grants Program Guidelines and Application Instructions proposalCENTRAL |
NEW
| May 04, 1:00pm | Postdocs | Non-federal | Career Development |
Stimulating Therapeutic Advancements through Research Training (START) Grants
START grants represent an exciting new initiative to encourage and support postdocs or clinical research fellows and combines research experiences in both academic and industry settings. Research proposed must have direct applicability to cancer with a specific focus on DNA Damage Response (DDR) pathways and may be basic, translational, or clinical in nature.| Due Dates: | May 02 (OSR) Ι May 04 (1:00pm, ET - Sponsor) |
| Amount & Project Period: | $225,000 - 3 years |
| Eligibility: | Applicant must
hold full-time research position of postdoc, clinical
research fellow, or equiv. for at least 1, but not more than 3 years,
and completed doctoral degree w/in past 1-3 years; Applicants who are not U.S. citizens or permanent residents must assure that visa status will provide sufficient time to complete project and grant term; Applicants must plan to spend 1 year on site at an AstraZeneca facility; AACR membership is required See Overview/Eligibility for additional details |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | Funding Opportunities Ι Program Guidelines and Application Instructions |
| U01 | NCI |
| May 05 (LOI) | All Ranks | Federal | "Traceback" testing |
Traceback Testing: Increasing Identification and Genetic Counseling of Mutation Carriers through Family-based Outreach (Clinical Trial Optional)
The purpose is to support pilot research projects using a "Traceback" approach to genetic testing women with a personal or family history of ovarian cancer and reaching out to family members to identify unaffected individuals at increased risk for cancer in different clinical contexts and communities, including racially/ethnically diverse populations.| Due Dates: | May 05 (Letter of Intent, Optional) Applications Due: June 01 (OSR) Ι June 05 (Sponsor) Additional Dates: Standard dates |
| Amount & Project Period: | Application budgets are not limited - 4 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-616 |
| R01 | NIH |
NEW
| May 06 (LOI) | All Ranks | Federal | Microbiota |
Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (Clinical Trial Optional)
The purpose is to assess the role of the microbiome in health and disease during aging. NCI will support applications for research to understand how changes in the aged microbiota and its metabolites relate to cancer risk, prevention, progression and treatment, as described in FOA.| Due Dates: | May 07 (Letter of Intent, Optional) |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-738 |
| Companion FOA: | PA-18-739 R21 |
| R01 | NIH |
| May 06 (LOI) | All Ranks | Federal | Disparities |
Surgical Disparities Research (Clinical Trial Optional)
The purpose is to support investigative and collaborative research focused on understanding and addressing disparities in surgical care and outcomes, in minority and health disparity populations. (See FOA for NCI topics of interest, Part II Section 1).| Due Dates: | May 06 (Letter of Intent, Optional) Applications Due: June 05 (OSR) Ι June 07 (Sponsor) Additional Due Date: June 7, 2019 |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-288 |
| Companion FOA: | PAR-18-289 R21 Clinical Trial Optional |
| R01 | NIH |
| May 07 (LOI) | All Ranks | Federal | CT/Prevention & Control |
Cancer Prevention and Control Clinical Trials Grant Program (Clinical Trial Required)
The purpose is to support investigator-initiated clinical trials having potential to reduce the burden of cancer through improvements in early detection, prevention, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, proposed studies should also have potential to improve clinical practice and/or public health. This FOA does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients.| Due Dates: | May 07 (Letter of Intent, Optional) Applications Due: June 01 (OSR) June 05 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-559 |
| Companion FOA: | PAR-18-560 (R01) |
| R01 | NIH |
| May 07 (LOI) | All Ranks | Federal | CT/Treatment & Diagnosis |
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (Clinical Trial Required)
The purpose is to support research projects implementing early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of NCI's Division of Cancer Treatment and Diagnosis (DCTD). Applications that propose phase III clinical trials in any area of cancer research will not be supported through this FOA.| Due Dates: | May 07 (Letter of Intent, Optional) Applications Due: June 01 (OSR) June 05 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | Limited to less than $500,000/yr. (Direct Costs) - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-560 |
| Companion FOA: | PAR-18-559 (R01) |
| Admin. Supplement | NIH |
NCI is a participating Institute
| May 07 | See Below | Federal | SGM Health |
Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Clinical Trial Optional)
This FOA supports administrative supplements to expand existing research to focus on Sexual and Gender Minority (SGM) health. Supplements will focus on areas of research interest, including, but not limited to: studies on increased disease risk; mental, behavioral and social health; approaches to personalized medicine; access to care; reproductive and sexual development; neurological and cognitive development; and resilience. In addition to contacting the IC Program Official for the approved award, applicants are strongly encouraged to include the Scientific/Research Contact listed in FOA on these communications.| Due Dates: | May 03 (OSR) Ι May 07 (Sponsor) |
| Amount & Project Period: | $100,000 (Total Costs) - Research proposed must be completed within the competitive segment of active award, and supplemental awards are for a one-year period. |
| Eligibility: | See FOA for
listing of mechanisms eligible for this supplement;
Parent award must have at least
18 months remaining at the time of request for supplement; Awards in no-cost extension periods are not allowed to submit an application in response to this FOA. |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-713 |
| R01 | NCI |
| May 07 (LOI) | All Ranks | Federal | Liver |
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (Clinical Trial Not Allowed)
The purpose is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the U.S.| Due Dates: | May 07 (Optional Letter of Intent, Optional) Applications Due: June 01 (OSR) Ι June 05 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-677 |
| Companion FOA: | PA-18-678 R21 (Standard dates) |
| U01 | NIH |
| May 08 | All Ranks | Federal | Biomedical |
Bioengineering Research Partnerships (Clinical Trial Optional)
This FOA Invites applications to accelerate development and adoption of promising tools and technologies that can address important biomedical problems. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project.| Due Dates: | May 04 (OSR) Ι May 08 (Sponsor) Additional Due Date: Sept. 13 |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-208 |
| Companion FOAs: |
PAR-18-206 R01 (Clinical Trial Optional) PA-18-286 R21 (Clinical Trial Optional) Due Dates: Standard dates for companion FOAs |
| U01 | NIH |
| May 09 (LOI) | All Ranks | Federal | Aging and Cancer |
Partnership for Aging and Cancer Research (Clinical Trial Not Allowed)
This FOA is a joint effort between NCI and NIA (that arose from discussions led by The Samuel Waxman Cancer Research Foundation (SWCRF)) to promote research regarding mechanisms by which aging affects cancer onset, progression, metastasis, and/or therapeutic response. To maximize collaborative interactions for this program, NIH extramural scientists will collaborate with investigators in the NCI Center for Cancer Research (NCI CCR) and/or the NIA Intramural Research Programs (NIA IRP) to address key questions on the aging contribution to cancer.| Due Dates: | May 09 (Letter of Intent, Optional) Applications Due: June 06 (OSR) Ι June 08 (Sponsor) |
| Amount & Project Period: | Not to exceed $75,000/yr. (Direct Costs) for extramural research component - 2 years |
| Eligibility: | All Ranks - An investigator from NCI Center for
Cancer Research must serve as co-investigator, and collaborators from
NIA and other divisions in NCI intramural research program are also
encouraged. Intramural collaborators should be tenured or tenure-track scientists and should have had previous contact with the PD(s)/PI(s) regarding the collaborative project proposed in the application. |
| Contact: | Office of Sponsored Research (x6804) |
| Additional Program Contact: | Samuel Waxman (212) 241-7995 |
| FOA Link: | PAR-18-552 |
| NCI Collaboration Links: |
NCI Intramural Program Directory of NCI Principal Investigators |
NEW
| May 10 | All Ranks | Non-federal | Drug Discovery |
Harrington Discovery Institute
2018 Scholar-Innovator Program
This award is based on breakthrough discovery defined by
innovation, creativity, and potential clinical impact including:
Discoveries deemed to address unmet medical needs; Novel
targets; Potential to be developed into a commercial
program; Possess intellectual property (IP) or protection
strategy; May be either a small molecule, biologic, or
other therapeutic modality; and Diagnostics or devices only
acceptable as part of a therapeutic development project or if
completely transformative.| Due Dates: | May 08 (OSR) Ι May 10 (Sponsor) |
| Amount & Project Period: | $100,000 guaranteed; opportunity to qualify for $700,000 - milestone based over 2 years |
| Eligibility: | Hold an MD,
MD/PhD ; Hold a faculty position at an accredited academic medical center, university or research institution; Project may have only a single PI; Past recipients of Harrington Scholar-Innovator awards may submit new and distinct proposals but may not seek additional support for previously funded projects |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | Award Program Details |
NEW
| May 10 | All Ranks | Non-federal | Ovarian |
The Rivkin Center for Ovarian Cancer
Bridge Funding Program
The purpose is to allow researchers to produce data needed to
substantiate a proposal resubmission to federal funding agencies
for a promising new research project. Researchers will have
submitted an R01 or R21 proposal to NIH or an original proposal
to the DoD pertaining to ovarian cancer, and not received, but
were close to, a fundable score. Investigator-initiated
projects in all areas of ovarian cancer research are eligible.
Special consideration will be given to research that has
clinical applicability.| Due Dates: | May 08 (OSR) Ι May 10 (Sponsor) |
| Amount & Project Period: | $30,000 - Bridge Funding Projects must have a duration of at least 6 months prior to resubmission to federal funding agency. |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | The Rivkin Center Grant Program Ι proposalCENTRAL |
| R01 | NIH |
NEW
| May 11 (LOI) | All Ranks | Federal | Nutrition & Nutrients |
Food Specific Molecular Profiles and Biomarkers of Food and Nutrient Intake, and Dietary Exposure (Clinical Trial Optional
This FOA calls for research on food specific molecular signatures and biomarkers of dietary consumption and to promote collaborative interactions among NIH and the United States Department of Agriculture - National Institute on Food Safety (USDA-NIFA) supported nutrition researchers.| Due Dates: | May 11 (Letter of Intent, Optional) Additional Due Dates: Sept. 27 and May 29 & Sept 27, 2019 |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-727 |
NEW
| May 11 (Pre-proposal) | Faculty Ranks | Non-federal | Brain Tumors |
Brain Tumor Funders' Collaborative (BTFC)
Immunotherapy for Primary Human Brain Tumors
This request for pre-proposals is focused on understanding the
complex dynamics among the constituents comprising the human
neuro-immune system, the heterogeneity of the primary brain
tumor, and the brain environment. Proposals are requested on
the role of the neuro-immune system in the origin and
progression of the immune responses in primary human brain
tumors in order to develop immunotherapies for treatment of
these tumors in patients. Pre-proposals should describe studies
on the complex roles of immune responses in the context of
primary brain tumors in pediatric and/or adult human patients. | Due Dates: | May 11 (Pre-proposals) Invited Submissions: Jul. 11 (OSR) Ι Jul. 13 (Sponsor) |
| Amount & Project Period: | $250,000/yr. - 3 years |
| Eligibility: | PI must hold a full-time faculty appointment;
Multi-disciplinary team-based projects |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | RFP Ι Brain Tumor Funders' Collaborative (BTFC) |
| May 14 | All Ranks | Federal | Big Data |
National Science Foundation (NSF)
Critical Techniques, Technologies and Methodologies for
Advancing Foundations and Applications of Big Data Sciences and
Engineering (BIGDATA)
The BIGDATA program seeks novel approaches leading towards
further development of the interdisciplinary field of data
science. The program also seeks innovative applications in
domain science, including social and behavioral sciences,
education, physical sciences, and engineering. The solicitation
invites two categories of proposals: 1. Foundations (BIGDATA: F): those developing or studying fundamental theories, techniques, methodologies, and technologies of broad applicability to big data problems, motivated by specific data challenges and requirements; and
2. Innovative Applications (BIGDATA: IA): those engaged in translational activities that employ new big data techniques, methodologies, and technologies to address and solve problems in specific application domains. Projects in this category must be collaborative, involving researchers from domain disciplines and one or more methodological disciplines, e.g., computer science, statistics, mathematics, simulation and modeling, etc.
| Due Dates: | May 10 (OSR) Ι May 14 (Sponsor) |
| Amount & Project Period: | Max. $500,000/yr. - 3 to 4 years |
| Eligibility: | All Ranks - Note: An individual may participate as PI, co-PI, Senior Personnel, consultant, or any other role in no more than one proposal, or related subaward, submitted in response to this solicitation. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | Solicitation:
18-539 Program Page: Critical Techniques, Technologies and Methodologies for Advancing Foundations and Applications of Big Data Sciences and Engineering (BIGDATA) |
| R01 | NIH |
NCI is a participating Institute
| May 14 | All Ranks | Federal | Native American Health |
Intervention Research to Improve Native American Health (Clinical Trial Optional)
The purpose of this funding opportunity announcement (FOA) is to encourage research to improve Native American (NA) health. NCI is interested in applications focusing on both individual and community interventions relating to primary and secondary cancer prevention and treatment. NCI is also interested in applications related to communication, attitudes, and knowledge of cancer risk factors (such as tobacco exposure, energy imbalance, and alcohol use).| Due Dates: | May 10 (OSR) Ι May 14(Sponsor) |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-17-473 |
| Companion FOA: | PAR-17-464, R21 |
| R01 | NCI |
| May 14 (LOI) | All Ranks | Federal | Tobacco & Health Disparities |
U.S. Tobacco Control Policies to Reduce Health Disparities (Clinical Trial Optional)
The purpose of this FOA is to support observational or intervention research focused on reducing cancer health disparities in tobacco use in the United States. It is specifically intended to stimulate scientific inquiry focused on innovative tobacco control policies.| Due Dates: | May 13 (Letter of Intent, Optional) June 11 (OSR) Ι June 13 (Sponsor) Additional Due Dates: Oct 11, 2018; June 13 & Oct. 11, 2019; and June 15, 2020 |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-675 |
| Companion FOA: | PAR-18-674 R21 |
NEW
| May 14 (LOI) | See Below | Non-federal | Ovarian |
Ovarian Cancer Research Fund Alliance
2019 Grants
Three grant programs are currently accepting letters of intent.
Please see information below.
| Due Dates: | May 14 (Letter of Intent) Invited Submissions: Jul. 19 (OSR) Ι Jul. 23 (Sponsor) |
| Contact: | Office of Sponsored Research (x6804) |
| Primary Link: | Application Process Ι proposalCENTRAL |
Ann and Sol Schreiber Mentored Investigator Award
This grant provides funding for trainees who are working under the supervision of a mentor who is a recognized leader in the field of ovarian cancer research, or relevant area.| Amount & Project Period: | $75,000 - 1 to 2 years |
| Eligibility: | Must be either
clinical fellows (Gynecologic Oncology, Medical Oncology) or
post-doctoral fellows and involved in either laboratory, clinical, or
epidemiology research. Must < 5 years from terminal degree at application (e.g. must have been awarded during 2013 or later); MDs must be currently enrolled in a fellowship program; At least 90% effort should be devoted to research during tenure of OCRFA award. |
| Link: | RFP |
Liz Tilberis Early Career Award
This award is intended for junior faculty with a strong commitment to an investigative career in the field of ovarian cancer research. The intent of these awards is to support a substantial time commitment to research and academic endeavors in ovarian cancer.| Amount & Project Period: | $150,000/yr. - 3 years (Applicants may have an opportunity to apply competitively for 1 grant renewal of 2 years at $100,000/yr. upon completion of first grant.) |
| Eligibility: | Must have MD or
Ph/D and be in first 5 years of first academic appointment
after completion of fellowship or post-doctoral training (Asst. Prof.
or equiv.); individuals who will begin such a position by July 2018 are
eligible; Awards will not be granted to individuals holding similar junior investigator awards from other funding agencies or foundations; Investigator and institution must certify that at least 75% of candidate's time will be dedicated to ovarian cancer research. |
| Link: | RFP |
Collaborative Research Development Grant
The purpose is to provide funds for ovarian cancer research projects that may involve several investigators w/in one institution or collaborations between groups in multiple institutions. Interdisciplinary collaborations are encouraged.| Amount & Project Period: | $300,000/yr. - 3 years (Applicants may be invited to apply for a one-time, 1 year competitive grant extension w/addnl. funding of $300,000). |
| Eligibility: |
PI (Single PI) and other investigators must have
full-time faculty appointments and not currently be in a training
program. International collaborations are welcome; Primary review criteria will be likelihood that investigators can leverage this funding to establish a research team capable of performing high-impact research and competing successfully for additional funding. |
| Link: | RFP |
NEW
| May 15 | See Below | Federal | Breast |
Congressionally Directed Medical Research Programs
Breast Cancer
Research Program
FY2018 Funding Opportunities
| Contact: | Office of Sponsored Research (x6804) |
| Primary Link: |
FY18 Breast Cancer Research Program (BCRP) Synopsis of FY18 BCRP Award Mechanisms |
Innovator Award
W81XWH-18-BCRP-INNOV
Supports visionary individuals who have demonstrated exceptional
creativity, innovative work, and paradigm-shifting leadership in
any field including, but not limited to, breast cancer. | Due Dates: | May 15 (Pre-application) Invited Applications Due: Aug. 10 (OSR) | Aug. 14 (Sponsor) |
| Amount & Project Period: | $5M (Direct Costs) - 4 years |
| Eligibility: | Must be at or
above Assoc. Professor (or equiv.) level; Must maintain 50% of full-time professional effort during award to breast cancer research; Previous recipients of a BCRP Innovator Award are ineligible; Research team is required to include two or more breast cancer consumer advocates. |
| Links: | Program Announcement Ι Application Instructions |
Distinguished Investigator Award
W81XWH-18-BCRP-DIA
Enables established visionary leaders from any field to pursue innovative
ideas that could accelerate progress toward ending breast
cancer. The central feature is that the PI must propose research
that is a fundamental, conceptual shift from his/her track
record of research and addresses one or more BCRP overarching
challenge(s) (See FOA).
| Due Dates: | May 15 (Pre-application) Invited Applications Due: Aug. 10 (OSR) Ι August 14 (Sponsor) |
| Amount & Project Period: | $3M - 4 years |
| Eligibility: | Must be at or
above Asst. Professor (or equiv.) level and >6 years beyond
the last mentored position. Research team is required to include two or more breast cancer consumer advocates. |
| Links: | Program Announcement Ι Application Instructions |
Breakthrough Award Levels 3 and 4
W81XWH-18-BCRP-BTA34
Supports promising research with high potential to lead to or
make breakthroughs in breast cancer. The critical components of
this award mechanism are Impact and Research Scope (detailed in
the program announcement). Funding Level 3: Supports advanced translational studies that have potential for near-term clinical investigation. Small-scale clinical trials may apply.
Funding Level 4: Supports large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Near-term clinical impact is expected. Human clinical testing is required. PIs are expected to have experience in successfully leading large-scale projects. A Partnering PI Option is included and structured to accommodate two PIs, referred to as the Initiating PI and the Partnering PI, each of whom will receive a separate award. See FOA for detail.
| Due Dates: | May 15 (Pre-application) Invited Applications Due: Aug. 10 (OSR) Ι August 14 (Sponsor) |
| Amount & Project Period: | Funding Level 3: $2.5M (Direct Costs) - 4
years Partnering PI Option: $4M (Direct Costs) - 4 years Funding level 4 (Single or Partnering): $10M - 4 years |
| Eligibility: | All Ranks - Each investigator may submit only one Funding Level 3 pre-application as a PI or Initiating PI and may also submit only one Funding Level 4 pre-application as a PI or Initiating PI. |
| Links: | Program Announcement Ι Application Instructions |
| May 16 | See Below | Federal | Breast |
Era of Hope Scholar Award
W81XWH-18-BCRP-EOH
Supports individuals early in their careers who have demonstrated
significant potential to effect meaningful change in breast
cancer. Important updates have been made to recently released program announcements for BCRP. Applicants must use updated application package, Program Announcements, and General Application Instructions. The following 2 updates have been made: (1) For all funding opportunities, the Research & Related Personal Data form is now a required form in the application package. (2) For the Partnering Principal Investigator (PI) Option in the Breakthrough Award Levels 1 and 2 and Levels 3 and 4, both the Initiating PI and Partnering PI must submit the Research & Related Senior/Key Personnel Profile (Expanded) form.
| Due Dates: | May 16 (Pre-application) Applications Due: May 25 (OSR) Ι May 30 (Sponsor) |
| Amount & Project Period: | $2.5M (Direct Costs) - 4 years |
| Eligibility: | Must be
independent investigator w/in 6 years of last training
position (e.g., postdoc; medical residency; clinical fellowship) as of
submission deadline; Must maintain 50% of full-time professional effort during award to breast cancer research; Research team is required to include two or more breast cancer consumer advocates. |
| Links: | Program Announcement Ι Application Instructions |
Breakthrough Award Levels 1 and 2 (No Clinical Trials)
W81XWH-18-BCRP-BTA12
Supports promising research with high potential to lead to or make
breakthroughs in breast cancer. The critical components of this
award mechanism are Impact and Research Scope (detailed in the
program announcement).Funding Level 1: Supports innovative, high-risk/high-reward research that is in the earliest stages of idea development. Research with potential to yield new avenues of investigation. Proof of concept. No preliminary data required.
Funding Level 2: Supports research that is already supported by preliminary data and has potential to make significant advancements toward clinical translation. A partnering PI Option is included and structured to accommodate two PIs, referred to as the Initiating PI and the Partnering PI, each of whom will receive a separate award. See FOA for detail.
| Due Dates: | May 16 (Pre-application) Applications Due: May 25 (OSR) Ι May 30 (Sponsor) |
| Amount & Project Period: | Funding Level 1: $375,000 (Direct Costs) – 3
years Partnering PI Option: $600,000 (Direct Costs) - 3 years Funding level 2: $750,000 - 3 years Partnering PI Option: $1M - 3 years |
| Eligibility: | All Ranks Senior postdoctoral fellows not meeting eligibility for BCRP Breakthrough Fellowship may apply. |
| Links: | Program Announcement Ι Application Instructions |
Breakthrough Fellowship Award
W81XWH-18-BCRP-BFA
Supports recent doctoral or medical graduates in pursuit of innovative,
high-impact breast cancer research during their postdoctoral
fellowship and allows them to obtain the necessary experience
for an independent career at the forefront of breast cancer
research.| Due Dates: | May 16 (Pre-application) Applications Due: May 25 (OSR) Ι May 30 (Sponsor) |
| Amount & Project Period: | $300,000 - 3 years |
| Eligibility: | Must have
completed requirements for doctoral and/or medical degree; Must have been in laboratory or clinical research setting where proposed research is to be performed for no more than 2 years as a postdoctoral researcher, and Must have a total of <4 years' experience in a postdoctoral fellowship or mentored clinical research training program (excluding any clinical residency or fellowship training); |
| Links: | Program Announcement Ι Application Instructions |
| R01 | NHGRI |
NEW
| May 21 (LOI) | All Ranks | Federal | Genomic Medicine |
Investigator-Initiated Genomic Medicine Research (Clinical Trial Optional)
This FOA supports research opportunities to advance understanding and implementation of the use of genomic information about an individual to inform clinical care, and the health outcomes of that clinical use.| Due Dates: | May 21 (Letter of Intent, Optional) Applications Due: June 18 (OSR) Ι June 20 (Sponsor) Additional Due Dates: Oct. 19 & June 20 and Oct. 21, 2019 |
| Amount & Project Period: | Must be under $500,000/yr. (Direct Costs) - 4 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-735 |
| Companion FOA: | PAR-18-736 R21 |
NEW
| May 21 | All Faculty Ranks | Non-federal | Childhood Cancer |
Alex's Lemonade Stand Foundation for
Childhood Cancer
2018 Reach Grants
Reach Grants are designed to move hypothesis-driven research into the
clinic. The grant is intended to fund developmental therapeutic
studies in the late stage of preclinical testing. A successful
application will identify an unmet clinical need relevant to the
care of pediatric patients with cancer and describe how the work
performed will allow for the translation to the clinic w/in two
years of completion. A plan and timeline for clinical testing
and trial implementation is expected. This grant does not fund
clinical trial expenses.
| Due Dates: | May 17 (OSR) Ι May 21 (Sponsor) |
| Amount & Project Period: | $250,000 - 2 years |
| Eligibility: | Assistant,
Associate or Professor level investigators w/track record of
discovery, investigation and external funding; Must have a demonstrated track record of pediatric cancer research w/experience in translational research. |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | 2018 Reach Guidelines |
| NCI participates | NIH |
| May 22 | All Ranks | Federal | Data-People-Systems |
National Science Foundation (NSF) and
National Institutes of Health (NIH)
Smart and Connected Health (SCH) Connecting Data, People and
Systems
The purpose of this interagency program, supported by NSF and
NIH, is to develop next-generation multidisciplinary science
that encourages existing and new research communities to focus
on breakthrough ideas in a variety of areas of value to health,
such as networking, pervasive computing, advanced analytics,
sensor integration, privacy and security, modeling of
socio-behavioral and cognitive processes and system and process
modeling. Effective solutions must satisfy a multitude of
constraints arising from clinical/medical needs, barriers to
change, heterogeneity of data, semantic mismatch and limitations
of current cyberphysical systems and an aging population. Such
solutions demand multidisciplinary teams ready to address issues
ranging from fundamental science and engineering to medical and
public health practice.
| Due Dates: | May 18 (OSR) Ι May 22 (Sponsor) Additional Due Date: Dec. 11th |
| Amount & Project Period: | $300,000/yr. (Total) - up to 4 years |
| Eligibility: | All Ranks - Note: An investigator may participate as PI co-PI, Project Director (PD), Senior Personnel or Consultant in no more than 2 proposals submitted in response to this solicitation. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | Smart and Connected Health Ι NSF 18-541 |
| May 25 | Postdocs/New Faculty | Non-federal | Career Development/Myelomas |
Multiple Myeloma Research Foundation (MMRF)
2018 Research Fellow Awards
The goal of this initiative is to help support young
investigators to begin their studies in the field of multiple
myeloma while advancing the understanding of myeloma disease
biology, treatment and drug resistance. | Due Dates: | May 23 (OSR) Ι May 25 (Sponsor) |
| Amount & Project Period: | $75,000 - 1 year |
| Eligibility: | Must hold a
Ph.D., M.D. or equiv. degree; Must be at post-doctorate, clinical fellow; OR Assistant professor level beginning studies in multiple myeloma field under supervision of a research mentor or sponsor; Mentor required for both Postdoc and faculty applicants |
| Contact: | Office of Sponsored Research (x6804) |
| Links: |
MMRF Research Grants Program Guidelines | proposalCENTRAL |
| R01 | NIH |
NEW
| May 30 (LOI) | All Ranks | Federal | Imaging |
Early Phase Clinical Trials in Imaging and Image-Guided Interventions
This FOA is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning and/or execution therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools.| Due Dates: | May 30 (Letter of Intent, Optional) Applications Due: June 24 (OSR) Ι June 28 (Sponsor) Additional 2018 Due Date: Oct. 11 |
| Amount & Project Period: | $500,000 (Direct Costs) for total period. No more than $250,000 (Direct Costs) may be requested in any single year. - 3 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-011 |
| R01 | NCI |
| May 30 (LOI) | All Ranks | Federal | Provocative Cancer Questions |
Research Answers to National Cancer Institute's (NCI) Provocative Questions (Clinical Trial Optional)
The purpose of these RFAs is to support research projects designed to solve specific problems and paradoxes in cancer research as identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.| Due Dates: | May 30 (Letter of Intent, Optional) Applications Due: June 27 (OSR) Ι June 29 (Sponsor) Additional 2018 Due Date: Oct. 30 |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| RFA Link: | RFA-CA-18-019 |
| Companion RFA: | RFA-CA-18-020 (R21) |
| Additional Note: | Four additional FOAs are planned for revision applications (formerly known as competing supplements) to add PQ-relevant research to specific eligible NIH and/or NCI-supported parent awards. Watch for RFA-CA-18-020, RFA-CA-18-022, RFA-CA-18-023, and RFA-CA-18-024 for R01, U01, P01, and P50 awards, respectively. |
| May 31 | All Ranks | Non-federal | Ovarian |
Louisa M. McGregor Ovarian Cancer
Foundation
2018 T.E.A.L.® Medical Research and Awareness
Program Beneficiary
This program offers funding in support of
ovarian cancer research studies that are most aligned with that
mission as determined by the T.E.A.L.® board of directors and
scientific advisory board. The mission is to promote public
awareness of and education about signs, symptoms, and risk
factors of ovarian cancer, provide support to survivors, and
raise funds for research in order to find a cure.| Due Dates: | May 29 (OSR) Ι May 31 (Sponsor) |
| Amount & Project Period: | Up to $50,000/yr. |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | T.E.A.L. ® Beneficiaries Ι Application |
| P50 | NCI |
NEW
| May 31 (LOI) | See Below | Federal | NCI Provocative Questions |
Revision Application to National Cancer Institute (NCI)-supported P50 Awards to Include Research on the NCI's Provocative Questions (Clinical Trial Optional)
This FOA invites revision applications from currently funded NCI P50 Program Projects. Revision applications are expected to focus on research related to one of the 12 NCI Provocative Questions (PQs) published in RFA-CA-18-019 and RFA-CA-18-020 intended for new R01 and R21 applications, respectively. Studies proposed in revision applications must correspond to a new research project expanding the scope, yet integrated into the overall theme, of the entire parent P50 award. To be responsive, each application must specifically address a particular scientific problem identified as one of the PQs.| Due Dates: | May 31 (Letter of Intent, Optional) Applications Due: June 27 (OSR) June 29 (Sponsor) Additional Due Date: Oct. 30th |
| Amount & Project Period: | May not exceed $150,000 /yr. (Direct Costs) for up to two (2) years, not to exceed remaining number of years on parent grant |
| Eligibility: | NCI P50 research
grants with at least two (2) years of support remaining on
parent grant at estimated time of award; PI (or Contact PI for multi- PI awards) on parent award must remain the same on a revision application; Parent grant must be active when application is submitted. If a no-cost extension is needed on parent grant, it must be in place before revision application is submitted |
| Contact: | Office of Sponsored Research (x6804) |
| RFA Link: | RFA-CA-18-024 |
| Companion RFAs: |
RFA-CA-18-021, R01 Research Project Grant RFA-CA-18-022, U01 Research Project - Coop. Agreement RFA-CA-18-023, P01 Research Program Projects |
| R01 | NCI |
| June 05 | All Ranks | Federal | Tumor Monitoring |
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (Clinical Trial Optional)
The purpose of this FOA is to support projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.| Due Dates: | June 1 (OSR) Ι June 05 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | MAX. $499,999/yr. (Direct Costs) - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-629 |
| R01 | NIH |
NEW
| June 05 | All Ranks | Federal | Gender Identity and Health |
Research on the Health of Transgender and Gender Nonconforming Populations (Clinical Trial Optional)
This FOA calls for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other.| Due Dates: | June 01 (OSR) Ι June 05 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-729 |
| Companion FOA: | PA-18-728 (R21) |
| R01 | NIH |
NEW
| June 05 | All Ranks | Federal | Treatment & Prevention Regimens |
Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (Clinical Trial Optional)
This FOA calls for research applications addressing patient adherence to treatment and prevention regimens to promote health outcomes. NCI seeks multi-level research from across the translational science continuum aimed at improving adherence to treatment and prevention regimens to reduce cancer risk, improve treatment outcomes, and lower cancer-related morbidity, mortality, and disability. Additional information about priority areas of research are described by the NCI's Division of Cancer Control and Population Sciences.| Due Dates: | June 01 (OSR) Ι June 05 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-722 |
| Companion FOA: | PA-18-723 R21 |
| R01 | NCI |
NEW
| June 05 | All Ranks | Federal | Tumor Cancer Therapy |
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (Clinical Trial Optional)
NCI seeks grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.| Due Dates: | June 01 (OSR) June 05 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | Limited to $499,999/yr. (Direct Costs) - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-629 |
| R21 | NIH |
| June 07 | All Ranks | Federal | Health Disparities |
Exploratory/Developmental Surgical Disparities Research (Clinical Trial Optional)
The purpose is to encourage developmental and exploratory research focused on understanding and addressing disparities in surgical care and outcomes, in minority and health disparity populations. The goal is to better understand and explore effectiveness of clinical intervention approaches for addressing surgical disparities, while employing multi-level strategies at the institutional and systems level.| Due Dates: | June 05 (OSR) Ι June 07 (Sponsor) Additional Due Date: June 07, 2019 |
| Amount & Project Period: | $275,000 - 2 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-289 |
| Companion FOA: | PAR-18-288 Surgical Disparities Research (R01 Clinical Trial Optional) |
| R01 | NIH |
NEW
| June 09 (LOI) | All Ranks | Federal | Druggable Genome |
Cutting Edge Informatics Tools for Illuminating the Druggable Genome (Clinical Trial Not Allowed)
The purpose of this FOA is to solicit applications to build a set of Cutting Edge Informatics Tools (CEITs) that will augment the capability of the Knowledge Management Center (KMC) as well as the broader Illuminating the Druggable Genome (IDG) Consortium.| Due Dates: | June 09 (Letter of Intent,
Required) Applications Due: Jul. 05 (OSR) Ι Jul. 09 (Sponsor) |
| Amount & Project Period: | Limited to $300,000/yr. (Direct Costs) - 2 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| RFA Link: | RFA-RM-18-011 |
NEW
| June 11 (LOI) | All Ranks | Non-federal | Surgical Technology |
Intuitive Surgical Technology
Research Grants
The purpose of these grants is to support technology research in the field
of surgical robotics, or related fields. Successful proposals
will address clinically-relevant technology development.
| Due Dates: | June 11 (Letter of Intent) Invited Submissions: Sept. 12 (OSR) Ι Sept. 14 (Sponsor) Note that an invitation to submit will include application guidelines and forms. |
| Amount & Project Period: | $10,000 to $50,000 - 1 year |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | Intuitive Surgical Research Grants Ι LOI Portal |
| R01 | NCI |
| June 11 (LOI) | All Ranks | Federal | Adducts/Adductomics |
Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention (Clinical Trial Not Allowed)
This FOA encourages research focused on adducts to cellular macromolecules as indicators of exposures to cancer risk factors relevant to human populations. Priority is on projects focusing on adductomic approaches, i.e., address some aspects of the totality of adducts. Projects should explore basic aspects of adducts/adductomics that may have potential utility in cancer detection, cancer prevention, and/or assessing cancer risks.| Due Dates: | June 11 (Letter of Intent, Optional) Applications Due: Jul. 09 (OSR) Ι Jul. 11(Sponsor) |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-704 |
| Companion FOAs: |
PAR-18-703, R21 PAR-15-307, U01 |
| R01 | NCI |
| June 13 | All Ranks | Federal | Smoking Cessation |
Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (Clinical Trial Optional)
This FOA is intended to stimulate research efforts aimed at the development of smoking cessation interventions that: 1) are targeted to socioeconomically disadvantaged populations, and 2) could be made scalable for broad population impact.| Due Dates: | June 11 (OSR) Ι June 13 (Sponsor) Additional Due Dates: Oct. 11 and June 13, 2019 |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-251 |
| Companion FOA: | PAR-18-250 R21 |
| R01 | NCI |
| June 13 | All Ranks | Federal | Cancer Communication |
Innovative Approaches to Studying Cancer Communication in the New Media Environment (Clinical Trial Optional)
This FOA invites applications seeking to apply one or more innovative methodologies in communication research across the cancer control continuum, from prevention, early detection, diagnosis, treatment, and survivorship, to end of life.| Due Dates: | June 11 (OSR) Ι June 13 (Sponsor) Additional Due Dates: Oct. 11 and June 13, 2019 |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-638 |
| Companion FOA: | PAR-18-639 R21 |
| R21 | NIH |
NEW
| June 16 | All Ranks | Federal | Obesity |
Exploratory/Developmental Clinical Research Grants in Obesity (Clinical Trial Optional)
NCI is interested in fostering research focused on identifying effective interventions for the prevention and treatment of obesity, including novel energy intake and expenditure modalities that alter body weight and/or composition in certain subpopulations of cancer patients and those at high risk for cancer.| Due Dates: | June 14 (OSR) Ι June 18 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | $275,000 (Direct Costs) - 2 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-720 |
| R21 | NIH |
NEW
| June 16 | All Ranks | Federal | Patient Adherence |
Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R21 Clinical Trial Optional)
This FOA calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. NCI seeks multi-level research from across the translational science continuum aimed at improving adherence to treatment and prevention regimens to reduce cancer risk, improve treatment outcomes, and lower cancer-related morbidity, mortality, and disability. Additional information about priority areas of research are described by the NCI's Division of Cancer Control and Population Sciences.| Due Dates: | June 14 (OSR) Ι June 18 (Monday, Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | $275,000 (Direct Costs) - 2 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-723 |
| Companion FOA: | PA-18-722 R01 |
| R21 | NIH |
NEW
| June 16 | All Ranks | Federal | Gender identity |
Research on the Health of Transgender and Gender Nonconforming Populations (R21 Clinical Trial Optional)
This FOA calls for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other.| Due Dates: | June 14 (OSR) Ι June 18 (Monday, Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | $275,000 (Direct Costs) - 2 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-728 |
| Companion FOA: | PA-18-729 R01 |
| R01 | NIH |
| June 17 (LOI) | All Ranks | Federal | Substance Abuse |
Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (Clinical Trial Optional)
As part of the Collaborative Research on Addiction at NIH (CRAN) initiative, NIDA, NIAAA, and NCI join to issue this FOA. The purpose is to support development and testing of interventions, models, and/or frameworks that examine system-level implementation of evidence-based interventions, guidelines, or principles to improve the delivery, uptake, quality, and sustainability of substance use prevention and treatment interventions and services.| Due Dates: | June 17 (Letter of Intent, Optional) Applications Due: Jul. 13 (OSR) Ι Jul. 17 (Sponsor) Additional 2018 Due Date: Nov. 13 |
| Amount & Project Period: | Max. $500,000/yr. (Direct Costs) - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-222 |
| Companion FOA: | PAR-18-223 R34 (Planning Grant) |
| R01 | NIH |
NEW
| June 19 | Junior/Early Stage Investigators | Federal | Basic Cancer Research/Diversity |
Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (Clinical Trial Not Allowed)
The purpose is to enhance the diversity of the pool of the cancer research workforce by recruiting and supporting eligible junior investigators and Early Stage Investigators from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical and social sciences. This funding opportunity will also provide a bridge to investigators who have completed their research training and may need extra time to develop a larger research project grant application.| Due Dates: | June 15 (OSR) Ι June 19 (Sponsor) Additional Due Dates: Nov. 19, 2018; & June 18, Nov. 19, 2019 |
| Amount & Project Period: | $275,000 (Direct Costs) - 2 years |
| Eligibility: | Junior and Early
Stage Investigators from groups that have been shown to be
nationally underrepresented in the biomedical workforce; Current or former PIs of an NIH R03 or R21 grant, or a non-federal equivalent to an R03 or R21 grant are eligible, but current or former PIs on an NIH research project grant (such as an R01), or any peer-reviewed non-NIH research grant over $175,000 direct costs/year are not eligible); An individual may receive no more than 2 awards from the Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research program, including past and future iterations of this FOA; By the time of award, PI must be a citizen or a non-citizen national of the U. S. or have been lawfully admitted for permanent residence (i.e., possess a currently valid Permanent Resident Card USCIS Form I-551, or other legal verification of such status). |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-731 |
| June 20 | See Below | Non-federal | Women's Cancers |
NEW
The Foundation for Women's Wellness
2018 Awards
| Due Dates: | June 18 (OSR) Ι June 20 (Sponsor) |
| Contact: | Office of Sponsored Research (x6071) |
| Primary Link: | Foundation for Women's Wellness |
2018 Research Awards
These research awards target early funding for small, short-term studies that hold promise for improving medical knowledge in leading female cancers. Applications should only be for studies that are exploring basic, clinical or epidemiological lines of inquiry.| Amount & Project Period: | $25,000 - 1 year |
| Eligibility: | Must be an M.D. and/or Ph.D. with a faculty appointment (assistant professor, or higher) |
| Link: | Research Awards |
2018 Fellowship Awards
Fellowship Awards recognize and support MD/PhD candidates or graduates pursuing fellowship or specialty training and working on research in women's health. Research focus is on focus is on basic, clinical or epidemiological lines of inquiry.| Due Dates: | June 20 (Submit directly to sponsor) |
| Amount & Project Period: | $25,000 - 1 year |
| Eligibility: | Must be currently
and/or be pursuing an MD and/or PhD and must still be in process of
completing education or medical training (specialty training,
fellowship); Applicants must have a social security number. Award checks go directly to individuals and will be reported to the IRS as required by federal law |
| Link: | Fellowship Awards |
| R01 | NIH |
| June 21 | All Ranks | Federal | Image-guided Drug Delivery |
Image-guided Drug Delivery (Clinical Trial Optional)
This FOA will support innovative research projects focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imaging-based systems for delivery of drugs or biologics in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention.| Due Dates: | June 19 (OSR) Ι June 21 (Sponsor) Additional 2018 Due Date: Nov. 22nd |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-252 |
| Admin. Supp. | NCI |
NEW
| July 01 | See Below | Federal | Data Sharing |
Research Supplements to Promote Data Sharing in Cancer Epidemiology Studies (Clinical Trial Not Allowed)
The purpose is to provide support to prepare and deposit individual-level data from cancer epidemiology studies into NIH/NCI-supported, controlled-access databases including the Cancer Epidemiology Data Repository (CEDR) and the database of Genotypes and Phenotypes (dbGaP). Sharing of research data will accelerate scientific discovery and increase opportunities for collaboration to provide new clues to cancer etiology, determine risk factors, and improve cancer survivorship.| Due Dates: | June 28 (OSR) Ι July 02 (Sponsor) |
| Amount & Project Period: | $150,000 (Total Costs) - 1 year Requests for no-cost extensions for parent grant to accommodate a supplement are not permitted. |
| Eligibility: | Supplement
available for existing projects with P01, U19, R01, U01 or
UM1 activity codes; Parent award must be active; Project/budget periods must be w/in currently approved project period of existing parent award. |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-748 |
NEW
| June 29 | All Ranks | Non-federal | General Cancer Research |
Phi Beta Psi Sorority
Annual Research Grant Award (Florida Grant)
(MCC Foundation-facilitated)
Phi Beta Psi's goal is to advance cancer research nationwide,
and grants are awarded only to investigators submitting
applications addressing the basic and clinical studies in the
field of cancer.
| Due Dates: | June 27 (OSR) Ι June 29 (Sponsor) |
| Amount & Project Period: | $20,000 - 1 year |
| Eligibility: | All Ranks |
| Contact: | Suzanne Knapp, Moffitt Foundation, (x1400) |
| Link: | How to Apply |
NEW
| July 01 | All Ranks | Non-federal | Fibrolamellar Hepatocellular Carcinoma |
Fibrolamellar Cancer Foundation
Research Grants
Research
must focus on Fibrolamellar Hepatocellular Carcinoma. Studies
should be intended to advance knowledge in the areas of FL-HCC.
Of particular interest are those showing a clear path to
clinical trials. Collaboration and open sourcing is a requirement
for FCF funding and will be so specified in any grant agreement. | Due Dates: | June 28 (OSR) Ι Jul. 01 (Sponsor) Additional Due Date: Jan. 01 Note: FCF is open to time sensitive requests - particularly for truly innovative ideas - throughout the year, as exceptions. |
| Amount & Project Period: | Application must reflect true amount necessary to conduct project. Duration is project dependent. If a multi-year grant is requested, FCF reserves the right not to continue funding after year one if insufficient advancements have been made and/or reporting protocol is not followed. |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | Apply for a Grant Ι Click here for Research Grant Application |
NEW
| July 06 | Faculty Ranks | Non-federal | Career Development |
Damon Runyon Cancer Research Foundation
Innovation Award
The Innovation Award is specifically designed to provide funding to
extraordinary early career researchers who have an innovative
new idea but lack sufficient preliminary data to obtain
traditional funding. It is not designed to fund incremental
advances. | Due Dates: | Jul. 03 (OSR) Ι Jul. 06 (Sponsor) |
| Amount & Project Period: | $300,000 - 2 years (A Stage 1 award will be for
two years; Stage 2 support for years three and four will be granted to those awardees who demonstrate progress on their proposed research during years one and two of the award.) |
| Eligibility: | Applicants must
belong to one of the following categories: Tenure-track
Asst. Professor w/in first 4 years of obtaining initial Asst. Professor
position. (Cut-off date: July 1, 2013);
Clinical Instructors and Senior Clinical Fellows (in final
year of sub-specialty training) holding an MD and pursuing a period of
independent research before taking a tenure-track faculty position, and
must have dedicated laboratory space and support of institution; Not eligible are Research Assistant Professors, Research Associate Professors, Research Scientists and Postdoctoral Fellows; Applicants are expected to commit at least 80% full time effort to conducting research. See award overview for additional eligibility details. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | Award Overview | Application Guidelines |
NEW
| July 09 | All Ranks | Non-federal | Cutaneous |
American Society for Dermatologic
Surgery
Cutting Edge Research Grant Program (CERG)
Submission of well-conceived research projects that stimulate
advancement of the practice of dermatologic surgery, the
invention of new technologies or research projects that document
the outstanding and high volume work of dermatologic surgeons
are encouraged. Specifically encouraged are proposals in the
areas of depth of training, scope of practice, safety and
efficacy as well as research with specific relevance in Core
surgical procedures and techniques; Cutaneous oncology; and new
technologies.| Due Dates: | Jul. 05 (OSR) Ι Jul. 09(Sponsor) |
| Amount & Project Period: | $20,000 |
| Eligibility: | All Ranks PD/PI must be ASDS member |
| Contact: | Office of Sponsored Research, x6804 |
| Links: | Overview Ι Application Site |
NEW
| July 15 | Postdocs | Non-federal | Research Award |
Science & SciLifeLab Prize for Young Scientists
Recent doctoral graduates in the life sciences may submit a 1,000-word essay based on their thesis work. Four winners - in the categories of Cell and Molecular Biology, Ecology and Environment, Genomics and Proteomics and Translational Medicine - will be selected for this international award.| Due Dates: | Jul. 15 (Sponsor) |
| The winners will: | Have their essay published by Science; $30,000 Grand Prize Winner; $10,000 ea. category winner; Be honored in Stockholm, Sweden in December. |
| Eligibility: | Entrants for the
2018 prize must have been awarded their Ph.D. between
January 1 2016 and December 31 2017; Prize will only recognize work that was performed while the entrant was a graduate student |
| Contact: | SciLifeLabPrize@aaas.org |
| Links: | Overview | How to Enter |
NEW
| July 20 | Postdocs & Junior Faculty | Non-federal | Career Development/Breast |
Breast Cancer Alliance
Young Investigator Grants
This award is intended for young researchers without their own
major grant support to encourage a commitment to breast cancer
research. Areas of relevant research may be, but not limited to,
diagnosis, etiology, immunology, genetics, therapies,
prevention, and clinical studies.| Due Dates: | Jul. 18 (OSR) Ι Jul. 20 (Sponsor) |
| Amount & Project Period: | $125,000 - 2 years |
| Eligibility: | Must have held
faculty position for no more than 4 years after completion
of training as of 02/01/2019;
Must not have been a PI on an
NIH R01 or equivalent national/international non-mentored award; Must dedicate at least 50% effort to research; Current postdocs are eligible if they meet all the other stated criteria for young investigators. |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | How to Apply |
Funding Opportunity Calendar
OSR's Grant News
grants.gov
NCI Funding Opportunities
NIH Guide to Grants & Contracts
RaceTracks
Federal Opportunities
Moffitt-Sponsored (Intramural) Opportunities
Opportunities Focused on Thoracic Oncology
Proposal Submission Form
Grants.gov Instructions
PHS398 Instructions
NIH 2590 Instructions
News
NIH Research Matters
The Cancer Letter
NIH News & Events
Federal Register
Science 360 News
PubMed
National Cancer Institute
Clinical Research
Who To Call in Clinical Research
Clinical Research FAQs
Data Safety Monitoring Plan
Liberty IRB
USF IRB
MRISignals@moffitt.org
